Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Abeona Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- Q2 NET ZEVASKYN REVENUE INCREASED 31% QUARTER-OVER-QUARTER TO $11.4 MILLION  - FIVE PATIENTS TREATED WITH ZEVASKYN IN Q2 2026 AND THREE TREATMENTS IN Q3 2026 TO-DATE; SINCE LAUNCH, 12 TREATMENTS COMPLETED  - EXPANDING QTC NETWORK NOW INCLUDES SEVEN SITES NATIONWIDE; GROWING NUMBER OF QTCS PROGRESSING PATIENTS THROUGH TREATMENT PROCESS  - $146.8 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF JUNE 30, 2026  CLEVELAND, AUG. 13, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND PROVIDED AN UPDATE ON COMMERCIAL EXECUTION FOR ZEVASKYN (PRADEMAGENE ZAMIKERACEL). COMMERCIAL UPDATE STEADY LAUNCH-YEAR GROWTH FOR ZEVASKYN.

ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES BUSINESS UPDATE

CLEVELAND, AUG. 06, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, AUGUST 13, 2026 AT 8:30 A.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND PROVIDE A CORPORATE UPDATE.

ABEONA THERAPEUTICS TO HOST SECOND QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 13, 2026

CLEVELAND, AUG. 04, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL AND GENE THERAPIES FOR SERIOUS DISEASES, TODAY ANNOUNCED THAT THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) HAS GRANTED NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) STATUS FOR ZEVASKYN (PRADEMAGENE ZAMIKERACEL) UNDER THE FISCAL YEAR 2027 HOSPITAL INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS) FINAL RULE. NTAP STATUS PROVIDES SUPPLEMENTAL CMS REIMBURSEMENT ABOVE STANDARD HOSPITAL PAYMENTS TO SUPPORT ACCESS TO INNOVATIVE THERAPIES LIKE ZEVASKYN.

CMS GRANTS NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) STATUS FOR ZEVASKYN

CLEVELAND, AUG. 03, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ABEONA THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

CLEVELAND, JULY 21, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL AND GENE THERAPIES FOR SERIOUS DISEASES, TODAY ANNOUNCED THE ACTIVATION OF CINCINNATI CHILDREN'S AS THE SEVENTH QUALIFIED TREATMENT CENTER (QTC) FOR THE ADMINISTRATION OF ZEVASKYN  (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY AUTOLOGOUS GENE-MODIFIED CELLULAR SHEETS FOR THE TREATMENT OF WOUNDS IN PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB). CINCINNATI CHILDREN'S IS ONE OF LARGEST EB CENTERS IN THE US AND WE ARE THRILLED TO ANNOUNCE ITS ACTIVATION AS A ZEVASKYN QTC.

CINCINNATI CHILDREN'S ACTIVATED AS THE SEVENTH QUALIFIED TREATMENT CENTER FOR ZEVASKYN

CLEVELAND, JULY 01, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CLEVELAND, JUNE 01, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CLEVELAND, MAY 26, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED THAT MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNE 2026:

ABEONA THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

- THREE PATIENTS TREATED WITH ZEVASKYN  IN Q1 2026 - - QTC NETWORK EXPANDS TO SIX SITES, WITH TWO NEW ADDITIONS ON THE EAST COAST - - IN-LICENSED RADICALLY NOVEL ENGINEERED T-CELL TECHNOLOGY WITH GAME CHANGING POTENTIAL IN THE FIELD OF SOLID TUMORS; OPHTHALMOLOGY PROGRAMS DEPRIORITIZED - - $168.3M IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2026 - - WEBCAST TODAY AT 8:30AM ET - CLEVELAND, MAY 13, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026, HIGHLIGHTING COMMERCIAL MOMENTUM FOR ZEVASKYN. STEADY INCREASE IN ZEVASKYN ADOPTION WITH THREE PATIENTS COMPLETING TREATMENT IN THE FIRST QUARTER OF 2026, ONE TREATMENT TO DATE IN THE SECOND QUARTER, ONE BIOPSY CURRENTLY IN MANUFACTURING PROCESS, AND SIX ADDITIONAL PATIENTS EXPECTED TO BE BIOPSIED IN THE SECOND QUARTER, THREE OF WHOM HAVE BIOPSIES SCHEDULED.

ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS AND PROVIDES PIPELINE UPDATE

CLEVELAND, MAY 11, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING GENETIC MEDICINES FOR SERIOUS DISEASES WITH HIGH UNMET NEED, TODAY ANNOUNCED ACTIVATION OF THE CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP) AS THE SIXTH QUALIFIED TREATMENT CENTER (QTC) FOR THE ADMINISTRATION OF ZEVASKYN (PRADEMAGENE ZAMIKERACEL) GENE-MODIFIED CELLULAR SHEETS. ACTIVATION OF CHOP IS A SIGNIFICANT STEP FORWARD FOR THE RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) COMMUNITY EXPANDING ACCESS TO ZEVASKYN IN THE EAST COAST, SAID DR. MADHAV VASANTHAVADA, CHIEF COMMERCIAL OFFICER OF ABEONA.

Abeona Therapeutics Inc.

ABEO

Price

Financial Reports

No items found.

Press Releases

Abeona Therapeutics Inc.

ABEO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABEO